Quoin Pharmaceuticals LtdNASDAQ:QNRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5850
- TODAY'S CHANGE (%)-0.0350 (-5.6452%)
- Bid / Lots0.5860/ 1
- Ask / Lots0.5900/ 2
- Open / Previous Close0.6100 / 0.6200
- Day Range
- 52 Week Range
- Volume68,860
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QNRX |
|---|---|---|
| 09:37 ET | 110 | 0.61 |
| 09:44 ET | 120 | 0.61 |
| 10:20 ET | 4600 | 0.61 |
| 10:22 ET | 704 | 0.6057 |
| 10:24 ET | 200 | 0.6016 |
| 10:26 ET | 1350 | 0.6097 |
| 10:29 ET | 9626 | 0.6057 |
| 10:31 ET | 260 | 0.6015 |
| 10:33 ET | 2530 | 0.6015 |
| 10:36 ET | 680 | 0.6 |
| 10:40 ET | 1305 | 0.6 |
| 10:42 ET | 122 | 0.6 |
| 10:54 ET | 7222 | 0.61 |
| 11:02 ET | 300 | 0.605 |
| 11:14 ET | 100 | 0.6 |
| 11:20 ET | 250 | 0.6001 |
| 11:25 ET | 2300 | 0.605 |
| 11:27 ET | 100 | 0.605 |
| 11:30 ET | 265 | 0.6002 |
| 11:32 ET | 466 | 0.6002 |
| 11:36 ET | 250 | 0.600793 |
| 11:38 ET | 299 | 0.6002 |
| 11:39 ET | 100 | 0.6002 |
| 11:54 ET | 7868 | 0.6 |
| 12:14 ET | 1111 | 0.599951 |
| 12:17 ET | 200 | 0.591 |
| 12:26 ET | 1998 | 0.59 |
| 12:28 ET | 1000 | 0.5979 |
| 12:30 ET | 169 | 0.6 |
| 12:32 ET | 1569 | 0.6 |
| 12:33 ET | 200 | 0.601 |
| 12:35 ET | 3603 | 0.5931 |
| 12:46 ET | 1000 | 0.6 |
| 12:51 ET | 100 | 0.6 |
| 01:13 ET | 4555 | 0.585 |
| 01:15 ET | 5601 | 0.5912 |
| 01:42 ET | 100 | 0.5912 |
| 02:14 ET | 500 | 0.6098 |
| 02:18 ET | 315 | 0.6 |
| 02:34 ET | 2500 | 0.592499 |
| 02:43 ET | 100 | 0.5925 |
| 02:50 ET | 100 | 0.585001 |
| 03:01 ET | 100 | 0.5937 |
| 03:19 ET | 149 | 0.5875 |
| 03:24 ET | 300 | 0.59145 |
| 03:26 ET | 300 | 0.5875 |
| 03:57 ET | 100 | 0.585 |
Nov 7, 2024
Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow JonesQuoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient, from 8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 31, 2024
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Quoin Pharmaceuticals Ltd | 3.1M | -0.1x | --- |
Actavia Life Sciences Inc | 3.1M | -7.5x | --- |
Bone Biologics Corp | 3.0M | -0.2x | --- |
Qualigen Therapeutics Inc | 3.3M | -0.1x | --- |
Shuttle Pharmaceuticals Holdings Inc | 2.9M | -0.1x | --- |
Genprex Inc | 3.0M | -0.1x | --- |
Company Information
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Contact Information
- Headquarters
- 23 Hata'as StreetKFAR SABA, Israel 44425
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Michael Myers
- Chief Financial Officer
- Eyal Leibovitz
- Chief Operating Officer, Vice President
- Amos Ofer
- Vice President - Research & Development & Product Development
- Amotz Nehushtan
- Internal Auditor
- Guy Sapir
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-6.64 |
Book Value | $5.74 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
